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REVIEW
Diosgenin, 4-Hydroxyisoleucine, and Fiber from
Fenugreek: Mechanisms of Actions and Potential
Effects on Metabolic Syndrome1,2
Scott Fuller3 and Jacqueline M Stephens3,4*
3Pennington Biomedical Research Center, Baton Rouge, LA; and 4Department of Biological Sciences, Louisiana State University, Baton Rouge, LA
ABSTRACT
Metabolic syndrome and its complications continue to rise in prevalence and show no signs of abating in the immediate future. Therefore, the
search for effective treatments is a high priority in biomedical research. Products derived from botanicals have a time-honored history of use in
the treatment of metabolic diseases including type 2 diabetes. Trigonella foenum-graecum, commonly known as fenugreek, is an annual
herbaceous plant that has been a staple of traditional herbal medicine in many cultures. Although fenugreek has been studied in both clinical
and basic research settings, questions remain about its efficacy and biologic mechanisms of action. Diosgenin, 4-hydroxyisoleucine, and the fiber
component of the plant are the most intensively studied bioactive constituents present in fenugreek. These compounds have been
demonstrated to exert beneficial effects on several physiologic markers including glucose tolerance, inflammation, insulin action, liver function,
blood lipids, and cardiovascular health. Although insights into the molecular mechanisms underlying the favorable effects of fenugreek have
been gained, we still do not have definitive evidence establishing its role as a therapeutic agent in metabolic disease. This review aims to
summarize the currently available evidence on the physiologic effects of the 3 best-characterized bioactive compounds of fenugreek, with
particular emphasis on biologic mechanisms of action relevant in the context of metabolic syndrome. Adv Nutr 2015;6:189–197.
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Introduction
Metabolic syndrome is a group of pathologies that includes
obesity, glucose intolerance, dyslipidemia, and hypertension
that are inextricably linked to diabetes mellitus and cardio-
vascular disease. Although the clinical features of metabolic
syndrome have been revised since the term was first coined
by Gerald Reaven in 1988 (1), its prevalence has increased to
epidemic proportions and constitutes a grave threat to pub-
lic health worldwide. This is especially alarming when con-
sidering the escalating incidence and prevalence of diabetes.
According to estimates issued by the International Diabetes
Federation, ~366 million people suffered globally from dia-
betes in 2011, and the number of diabetes cases is projected
to increase to 552 million by 2030 (2). The United States
stands as one of the most severely afflicted nations. The
CDC estimated the number of diagnosed cases at 18.8 mil-
lion, with roughly 7 million undiagnosed cases (3).
Despite the availability of several drugs effective for the
treatment of pathologies associated with metabolic syndrome,
particularly diabetes, there are disadvantages associated with
long-term use of some of the relevant pharmaceuticals. Side
effects and cost must be considered, especially because the in-
cidence of diabetes continues to climb in the developing
world, where access to conventional drugs is limited. Hence,
the identification of natural products that are effective in ame-
liorating diabetes is a worthwhile endeavor.
Trigonella foenum-graecum (fenugreek) is an annual plant
native to India and North Africa that has a long history of
use in cooking and as a traditional herbal medicine in the
treatment of a variety of conditions, including diabetes
and hyperlipidemia (4, 5). Fenugreek has been studied in
humans and animals and there is considerable evidence to
suggest that it possesses therapeutic properties applicable
to metabolic disease (6–8). Although therapeutics derived
from plant sources are, in general, attractive because of their
relative safety and tolerability compared with currently
available pharmaceuticals, a 2011 outbreak of hemolytic-
uremic syndrome in Germany, which affected 3842 people
and caused 53 deaths, was caused by a strain of shiga
1 Supported by a postdoctoral training fellowship T32 AT004094 (to SF) awarded to
Pennington Biomedical Research Center.
2 Author disclosures: S Fuller and JM Stephens, no conflicts of interest.
* To whom correspondence should be addressed. E-mail: jsteph1@lsu.edu.
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toxin–producing Escherichia coli in which contaminated
fenugreek sprouts were identified as the most likely trans-
mission vehicle (9, 10). This incident highlights the need
for careful safety measures and standardization of botanical
products before they are made available in the marketplace
(11, 12).
This review aims to summarize the body of literature that
has evaluated the safety and efficacy of 3 of the most com-
prehensively studied bioactive compounds present in fenu-
greek: diosgenin, 4-hydroxyisoleucine (4-OH-Ile)5, and the
soluble dietary fiber fraction of fenugreek seeds. A particular
area of emphasis is an analysis of the effects of these bioac-
tive chemical components on biologic mechanisms control-
ling peripheral insulin action, glucose homeostasis, and
maintenance of normal blood lipids. This analysis provides
a starting point for future research aimed at evaluating the
potential of fenugreek as a potential therapeutic in the ongo-
ing quest to develop new strategies for the treatment of met-
abolic syndrome and its complications.
Diosgenin
Diosgenin is a biologically active steroid sapogenin present
in fenugreek. Diosgenin has been proposed to be effective
against a variety of pathologies, including diabetes, hyperlip-
idemia, cancer, cardiovascular disease, oxidative stress, and
inflammation (13–18). Studies assessing diosgenin for toxic-
ity have shown that the compound is generally well tolerated
orally in doses of up to ~500 mg/kg (19, 20). In assessing the
potential of fenugreek as a therapeutic agent in combating
diabetes, diosgenin has emerged as an important mediating
factor in several of the biologic effects of fenugreek that con-
tribute to the maintenance of insulin signaling and glucose
homeostasis (Figure 1).
The most recent experimental evidence supporting a role
for diosgenin as an antidiabetic agent has come from studies
examining its effectiveness in reducing glycemia in animal
models of diabetes induced pharmacologically (15, 21–23)
or by a combination of drugs and diet (21, 23), although
in vitro approaches have also been used (14, 24). These stud-
ies, largely performed in rodents, have assessed the effects of
diosgenin on glycemic control in models of both type 1 and
type 2 diabetes. These investigations have focused on various
target tissues critical to the preservation of glucose homeo-
stasis, including the pancreas, liver, and skeletal muscle. This
research has yielded considerable insight into the molecular
mechanisms underlying the potential of diosgenin as an an-
tidiabetic agent. Mechanisms of action attributed to dios-
genin in ameliorating experimentally induced diabetes
include restoration of pancreatic b-cells (15, 21), downregu-
lation of enzymes involved in hepatic gluconeogenesis and
glucose export, upregulation of hepatic glucokinase, and in-
creases in the amounts of hepatoprotective and antioxidant
enzymes (15). Additionally, studies have begun to explore how
diosgenin modulates adipose tissue function, which plays a
key role in maintaining glycemic control (24). A review of the
studies examining the effect of diosgenin on physiologic markers
involved in metabolic syndrome is provided (Table 1).
Endoplasmic reticulum (ER) stress and the unfolded pro-
tein response have been implicated in the pathogenesis of in-
sulin resistance and diabetes, specifically in the context of
b-cell dysfunction (25, 26). In a series of experiments in
streptozotocin-induced type 2 diabetic rats, diosgenin atten-
uated pancreatic ER stress by reducing expression of the
C/EBP homologous protein (CHOP) and caspases 12 and 3
(21). Diosgenin also restored normal pancreas morphology,
improved serum glucose and insulin concentrations, in-
creased amounts of antioxidant enzymes, and enhanced
PPARg expression (21). These findings were supported by
a study with streptozotocin-induced diabetic rats. In this
study, blood glucose (BG), glycated hemoglobin, serum
LDL, total cholesterol (TC), serum TGs, alanine transam-
inase, glucose-6-phosphatase, serum HDL, pancreatic
b-cell number, and the concentrations of several antioxidant
enzymes were all restored to normal after 30 d of treatment
with a daily oral dosage of 10 mg/kg of diosgenin (15).
Further evidence confirming the antidiabetic potential of
diosgenin was reported in a similar study with streptozotocin-
induced diabetic rats, in which 45 d of oral administration
of diosgenin at increasing doses (15, 30, and 60 mg/kg)
resulted in a restoration of BG, carbohydrate metabolic en-
zymes, and glycogen content to near normal concentrations
(22). These recent animal studies are in general agreement
with diosgenin exerting protective effects on pancreatic func-
tion and suggest an important mechanism by which this com-
pound could reverse several of the hallmark abnormalities
characteristic of diabetes and metabolic syndrome in general.
The storage of lipids in parts of the body other than ad-
ipose tissue, known as ectopic fat accumulation, is a classic
feature of metabolic syndrome intimately linked to one of its
most damaging clinical consequences, cardiovascular disease
(27–31). Inhibition of abnormal fat deposition is therefore a
valuable component of any treatment strategy for metabolic
syndrome. Of all the possible sites of ectopic lipid accumu-
lation, the liver is probably the best studied (32, 33). Lipid
synthesis in the liver is under the control of sterol regulatory
element–binding proteins (SREBPs). The transcription fac-
tor SREBP-1c is vital for TG synthesis because it regulates
the expression of several genes integral to FA metabolism
in the liver, including acetyl-CoA carboxylase (ACC), FA
synthase, and stearoyl-CoA desaturase (SCD-1) (34). Liver
X receptor-a (LXRa) is an important regulator of SREBP-1c
and thus plays an important role in the regulation of
FA synthesis in the liver (35). A study with 4 wk of fenugreek
dietary supplementation decreased plasma and hepatic TGs
in KK-Ay mice subjected to a high-fat diet (HFD) (36). Gene
expression analysis revealed that hepatic mRNA expression
of SREBP-1c and other lipogenic genes were suppressed in
5 Abbreviations used: ACC, acetyl-CoA carboxylase; BG, blood glucose; CHOP, C/EBP
homologous protein; ER, endoplasmic reticulum; ERK1/2, extracellular signal-related kinases
isoforms 1 and 2; GLUT4, glucose transporter 4; GSK-3b, glycogen synthase kinase-3b; HFD,
high-fat diet; IRS-1, insulin receptor substrate 1; JNK, c-Jun N-terminal kinase; LXRa, liver X
receptor-a; MCP-1, monocyte chemotactic protein 1; NPC1L1, Niemann-Pick C1 like 1; PI3K,
phosphatidylinositide 3-kinase; SCD-1, stearoyl-CoA desaturase 1; SREBP-1c, sterol
regulatory element–binding protein 1-c; TC, total cholesterol; 4-OH-Ile, 4-hydroxyisoleucine.
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the fenugreek-treated mice. Follow-up mechanistic studies
in HepG2 cells demonstrated that diosgenin isolated from
fenugreek accounted for fenugreek’s effects on hepatic lipid
accumulation via inhibition of LXRa transactivation, which
in turn decreased mRNA induction of SREBP1-c and its tar-
get genes (36). Confirmation of these findings was reported
in a recent study in streptozotocin-induced diabetic rats
showing that diosgenin administered for 14 d significantly
reduced HFD-induced hyperglycemia and hyperlipidemia
(23). Although further corroboration of these results would
be advantageous, the currently available evidence supports
the hypothesis that diosgenin attenuates abnormal hepatic
lipid metabolism in vitro and in vivo.
The discoveries of the adipocyte-derived hormones leptin
and adiponectin during the 1990s have led to recognition
of the indispensable role played by adipose tissue in the
TABLE 1 The effect of diosgenin on markers relevant to metabolic syndrome1
Model Experimental outcomes Reference
3T3-L1 adipocytes, RAW
264 macrophages
YMCP-1, YTNF-a, YNF-kB Hirai et al. (14)
Streptozotocin-induced
diabetic rats
YBG, Yserum LDL, Yserum TC, [serum HDL,
YHb A1c, YALT, YAST, YG6P, [SOD, [catalase, [GSH, [GK
Kalailingam et al. (15)
Streptozotocin-induced
diabetic rats
YBG, YHb A1c, [total Hb, [SOD, [catalase, [GSH, YFI Pari et al. (16)
Streptozotocin-induced
diabetic rats
YSerum TC, [serum HDL, YTBARS, [SOD, [GPx, [catalase Son et al. (18)
Type 2 diabetic rats YFFA, YTNF-a, YIL-6, [leptin, [PPARg, Yendoplasmic reticulum stress Tharaheswari et al. (21)
Streptozotocin-induced
diabetic rats
YBG, [liver glycogen Saravanan et al. (22)
Type 2 diabetic rats, 3T3-L1
adipocytes
YBG, Yserum TC, Yserum TG,YROS, [SOD, [GSH, [neutral lipid accumulation Sangeetha et al. (23)
Diabetic obese KK-Ay mice YAdipocyte size, [adipogenesis, Ymacrophage infiltration,
Yadipocyte inflammation
Uemura et al. (24)
Diabetic obese KK-Ay mice,
HepG2 cells
YSerum TG, YSREBP-1c, YFAS, YSCD-1, YACC, Yhepatic
steatosis, YLXRa activation
Turer et al. (37)
NPC1L1-knockout C57BL6 mice [Cholesterol excretion, [biliary cholesterol secretion,
Yserum TC, Yhepatic cholesterol




YIKK-b, YNF-kB, YTNF-a, YIL-6, [IRS-1, [PI3K, [Akt, [eNOS, YPAI-1 Manivannan et al. (49)
Chronic renal failure rats [Vascular relaxation, [GSH, [eNOS, Yserum TG, YACE activity Manivannan et al. (50)
Chronic renal failure rats [GSH, [SOD, [catalase, Ylipid peroxidation, [NO production Salimeh et al. (51)
MI-induced rats [GSH, [SOD, [catalase, Ylipid peroxidation, Yarea of infarction Badalzadeh et al. (53)
Hypertensive rats YROS, YTNF-a, YiNOS, [eNOS, YMAP Ebrahimi etal. (54)
Ischemic rats YLDH, YPVC, YVT, YVF Liu et al. (48)
Ischemic rats YTNF-a, YIL-6, YIL-1b, YLDH, [cardiac contractility Manivannan et al. (55)
1 ACC, acetyl-CoA carboxylase; ACE, angiotensin-converting enzyme; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BG, blood glucose; eNOS, endothelial NO
synthase; FAS, FA synthase; FI, fasting insulin; G6P, glucose 6-phosphatase; GK, glucokinase; GSH, reduced glutathione; GPx, glutathione peroxidase; Hb A1c, glycated hemo-
globin; IKK-b, inhibitor of NK-kB kinase subunit-B; iNOS, inducible NO synthase; IRS-1, insulin receptor substrate 1; LDH, lactate dehydrogenase; LXRa, liver X receptor-a; MAP,
mean arterial pressure; MCP-1, monocyte chemotactic protein 1; MI, myocardial infarction; NPC1L1, Niemann-Pick C1 like 1; PAI-1, plasminogen activator inhibitor type 1; PI3K,
phosphatidylinositide 3-kinase; PVC, preventricular contraction; ROS, reactive oxygen species; SCD-1, stearoyl-CoA desaturase 1; SOD, superoxide dismutase; SREBP-1c, sterol
regulatory element–binding protein 1-c; TC, serum total cholesterol; total Hb, total hemoglobin; VF, ventricular fibrillation; VT, ventricular tachycardia; [, increase in amount or
incidence; Y, decrease in amount or incidence.
FIGURE 1 The 3 main bioactive compounds of
fenugreek and their mechanisms of action. The
pancreas, skeletal muscle, liver, adipose tissue, and
gut are major tissue targets of fenugreek through
which serum markers such as glucose, insulin,
and lipids are favorably modulated and metabolic
health could thereby be improved. ACC, acetyl-
CoA carboxylase; Akt-PSer473, Akt
phosphorylated on Ser 473; CHO, carbohydrate;
FAS, FA synthase; LXRa, liver X receptor-a; PI3K,
phosphoinositide 3-kinase; SCD-1, stearoyl-CoA
desaturase 1; SREBP1-c, sterol regulatory
element–binding protein 1-c; TC, serum total
cholesterol; 4-OH-Ile, 4-hydroxyisoleucine.
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maintenance of proper metabolic function (37, 38). The se-
cretory factors produced by fully functional adipose tissue
not only serve to sustain insulin sensitivity and glucose ho-
meostasis but also regulate feeding behavior (39, 40). Con-
versely, when adipocyte function is compromised and
inflammation occurs, it results in adverse metabolic conse-
quences (41). Although there is a great deal of literature sup-
porting the use of fenugreek as an antidiabetic agent, efforts
to understand how bioactive compounds from this botanical
could beneficially modulate adipocyte metabolism are in
their infancy. However, some evidence supporting a role
for diosgenin in enhancing adipocyte function has recently
emerged. Diosgenin has anti-inflammatory properties in a
coculture model with 3T3-L1 adipocytes and RAW macro-
phages. In this study diosgenin significantly decreased the
production of the proinflammatory mediators TNF-a,
monocyte chemoattractant protein 1 (MCP-1), and NO (14).
Diosgenin can also promote adipocyte differentiation. An
in vitro study of 3T3-L1 adipocytes revealed that diosgenin
treatment enhanced adipogenesis and lipid accumulation
while also reducing the expression of inflammatory factors
(24). In addition, it was demonstrated that fenugreek ame-
liorated diabetes, reduced adipose tissue inflammation, de-
creased adipocyte size, inhibited macrophage infiltration
into adipose tissue, and increased the mRNA expression of
adipogenic genes in KK-Ay mice challenged with HFD
(24). Although confirming the antidiabetic effect of dios-
genin in streptozotocin-induced diabetic rats, a recent study
has also demonstrated that diosgenin exerts its adipogenic
effects at least in part by acting as a PPARg agonist (23).
These findings are of substantial interest because of the crit-
ical function played by PPARg as the master genetic regula-
tor of adipocyte differentiation and the chief molecular
target of several insulin-sensitizing drugs (42). The thiazoli-
dinediones, in particular, promote insulin sensitivity through
their activation of PPARg and the effectiveness of this class
of drugs in the treatment of type 2 diabetes has been well es-
tablished. However, adverse events associated with their use
are widely reported in the literature and their use is associ-
ated with increased risk of weight gain, fluid retention, bone
loss, and congestive heart failure (43, 44). In view of both
the benefits and the risks associated with the use of thiazo-
lidinediones, the development of antidiabetic agents with
the insulin-sensitizing effects of classic PPARg agonists
without the undesirable side effects would provide attractive
new therapeutic possibilities. Future work in this area is
worthwhile and botanical products such as fenugreek con-
taining diosgenin could have great potential in this area of
investigation.
Evidence has also indicated that diosgenin could be use-
ful in the treatment of metabolic disease by regulating cho-
lesterol homeostasis. Aside from the studies in obese diabetic
animals discussed previously, which showed that dios-
genin treatment was effective in reversing hyperlipidemia,
mechanistic studies indicate that diosgenin affects serum
lipids by enhancing biliary cholesterol excretion (45). Dios-
genin promotes fecal cholesterol excretion independently
of Niemann-Pick C1-like 1 (NPC1L1), a protein present
in the apical membrane of absorptive enterocytes that regu-
lates intestinal cholesterol absorption and is targeted by eze-
timibe, a cholesterol-lowering drug (45, 46). This finding is
of interest in the context of botanical remedies because cur-
cumin, a bioactive compound present in turmeric, lowers
cholesterol through an NPC1L1-dependent mechanism
(47). This raises the possibility that supplementation with
turmeric and fenugreek could act additively in lowering cho-
lesterol, although experimental evidence supporting this
concept is still unavailable.
Diosgenin has also displayed potential as a therapeutic
adjunct in the treatment of cardiovascular disease. Animal
studies in the last few years have yielded evidence demon-
strating that diosgenin enhances endothelial function and
inhibits inflammation, insulin resistance, and oxidative
stress in the vasculature induced by diabetes and palmitate
treatment (16, 48). Recent studies in animal models of
chronic renal failure have shown that diosgenin protects vas-
cular function by attenuating aortic calcification, increasing
the expression of endothelial NO synthase, and inhibiting
osteochondrogenic differentiation in aortic vascular smooth
muscle cells (49, 50). Further evidence for the cardioprotec-
tive effects of diosgenin has emerged from animal studies us-
ing several models of cardiovascular disease including
pulmonary hypertension, ischemia-reperfusion injury, and
isoproterenol-induced myocardial infarction (51–54). These
studies support the general conclusion that diosgenin pos-
sesses anti-inflammatory, antioxidant, and vasodilatory prop-
erties. These attributes support a potential role for diosgenin
in reducing cardiovascular disease risk.
The evidence thus far reported in the literature on dios-
genin supports the idea that this fenugreek component
exerts beneficial effects on several physiologic markers
relevant to metabolic syndrome. Diosgenin exerts effects
on the pancreas, liver, skeletal muscle and adipose tissue
that restore insulin sensitivity, glucose homeostasis, and
normal blood lipids in diabetic animals (Figure 1) (15, 21,
22, 24, 48). By restoring pancreatic b-cell function and at-
tenuating pancreatic ER and oxidative stress diosgenin has
been shown to promote insulin secretion and preserve nor-
mal glucose concentrations even in the presence of negative
stimuli such as streptozotocin treatment or HFD (21). Fur-
thermore, diosgenin can enhance insulin action in skeletal
muscle and adipose tissue (21, 22, 24). This enhanced insu-
lin action in peripheral tissues, acting in a concerted manner
with augmented insulin secretion, likely accounts for the
advantageous effects on glucose metabolism observed in di-
abetic animals treated with diosgenin. Additional mechanisms
underlying the favorable metabolic effects of diosgenin are re-
duced hyperlipidemia mediated by increased biliary choles-
terol excretion and reduced hepatic lipid accumulation via
inhibition of LXRa, SREBP-1c, and other lipogenic factors
in the liver (36, 45). Moreover, diosgenin positively modulates
vascular function and thereby could act as a cardioprotective
agent (16, 48, 49, 53–55). Taken together, these studies on di-
osgenin have yielded valuable insight on how this bioactive
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compound and fenugreek could promote metabolic health in
an obesogenic environment.
4-OH-Ile
4-OH-Ile is a novel branched-chain amino acid derivative
that has been shown to be present in fenugreek seeds and
has been postulated to account, at least in part, for fenu-
greek’s antidiabetic effects. 4-OH-Ile is only present in
plants and is particularly abundant in fenugreek seeds,
where it comprises ~80% of the total content of free amino
acids (56–58). The first studies investigating the antidiabetic
properties of 4-OH-Ile determined that its effects on glyce-
mia were attributable to its potency in stimulating insulin
secretion (57). This insulinotropic effect was initially dem-
onstrated in isolated rat and human pancreatic islet cells
and in isolated perfused rat pancreas (57). Additional in
vivo studies confirmed and extended these findings to ani-
mal models, where improved glucose and insulin tolerance,
improved insulin secretion, and reduced hyperglycemia
were observed in both diabetic and normal rats and dogs
(59). A recurring finding of particular interest from these
studies was the observation that 4-OH-Ile functioned as
an insulin secretagogue only in the presence of elevated
BG concentrations in the moderate (8.3 mM) to high
(16.7 mM) range (57, 59, 60).
Although reversing defective insulin secretion is clearly
beneficial in a diabetic state, enhancing insulin sensitivity
in hepatic and peripheral tissues is also a valuable treatment
modality. Broca and colleagues (61) conducted the first
reported studies that specifically assessed the potency of
4-OH-Ile as an insulin-sensitizing agent. The results of these
experiments demonstrated the efficacy of 4-OH-Ile as an in-
sulin sensitizer in 2 rat models. Using the hyperinsulinemic
clamp method, improvements in insulin sensitivity were de-
tected in sucrose-lipid–fed rats, where peripheral glucose up-
take was increased, and in Zucker fa/fa rats, where hepatic
glucose output was decreased. Acute in vivo injection of
4-OH-Ile also resulted in the insulin receptor substrate
1 (IRS-1)–related activation of phosphatidylinositide 3-kinase
(PI3K) in insulin-sensitive tissues (61).
Recent studies have revealed further insight into the ther-
apeutic properties of 4-OH-Ile by probing its effects in ani-
mal models of diabetes and dyslipidemia. Narender et al.
(62) broadened the scope of previous investigations by
studying the effect of 4-OH-Ile on dyslipidemia. In this
study, results showed that treatment of dyslipidemic ham-
sters with 4-OH-Ile led to decreases in plasma TGs, TC,
and FFAs while simultaneously increasing the ratio of serum
HDL cholesterol:TC by 39%. Haeri and colleagues (63)
examined the effect of 4-OH-Ile from fenugreek in
streptozotocin-induced diabetic and fructose-fed rats and
demonstrated that markers of liver function and glycemic
control improved after 8 wk of treatment at a dose of
50 mg/kg. Specifically, the authors found that in fructose-fed
rats BG and markers of liver damage (aspartate aminotrans-
ferase and alanine aminotransferase) were restored to
amounts near those observed in control animals, whereas
in streptozotocin-diabetic rats serum HDL cholesterol in-
creased. Further confirmation of the antidiabetic and anti-
dyslipidemic effects of 4-OH-Ile were observed in the
leptin receptor–deficient db/db mouse; improvements in
BG, insulin, and blood lipids were reported after treatment
with 4-OH-Ile (64). The beneficial effects of 4-OH-Ile ap-
pear to be also applicable to a model of type 1 diabetes,
where 4 wk of 4-OH-Ile treatment decreased BG while con-
comitantly restoring blood lipid and uric acid concentra-
tions to those found in normal nondiabetic controls (65).
The latest research efforts aimed at understanding the
molecular mechanisms of 4-OH-Ile action have used cell
culture models. In cultured rat muscle cells, glucose uptake
and glucose transporter 4 (GLUT4) translocation to the
plasma membrane were increased in response to a 16-h ex-
posure to 4-OH-Ile (66). Additionally, 4-OH-Ile treatment
increased the basal phosphorylation of Akt (Ser-473), while
mRNA expression of total Akt, IRS-1, GLUT4, and glycogen
synthase kinase-3b (GSK-3b) were unchanged. Another
group extended these findings in cultured muscle cells by
demonstrating that 4-OH-Ile ameliorated FA-induced insu-
lin resistance in L6 myotubes (67). These experiments
showed that 4-OH-Ile restored insulin-stimulated glucose
uptake and GLUT4 recruitment to the plasma membrane
in response to palmitate treatment via induction of IRS-1
phosphorylation. Interestingly, this was the first study to
demonstrate that 4-OH-Ile could inhibit both the palmitate-
induced production of reactive oxygen species and the as-
sociated inflammation, as was demonstrated by reduced
activation of NF-kB, c-Jun N-terminal kinase isoforms
1 and 2 (JNK1/2), extracellular signal-regulated kinase iso-
forms 1 and 2 (ERK1/2), and p38 MAPK (67).
An understanding of the effects of 4-OH-Ile on adipo-
cytes in the context of insulin resistance and diabetes re-
mains a relatively undeveloped area of investigation. To
date, only 1 study has examined the effects of 4-OH-Ile on
adipocytes (68). This study demonstrated that treatment
with 4-OH-Ile increased glucose uptake in insulin-resistant
3T3-L1 adipocytes in a dose-dependent manner. 4-OH-Ile
also showed potential as an anti-inflammatory agent by re-
ducing TNF-a mRNA expression and secretion. Given the
growing recognition of the importance of the adipocyte in
the maintenance of glucose homeostasis and insulin sensi-
tivity, further studies of the effects of 4-OH-Ile on adipocyte
function will be critical in development of 4-OH-Ile and
other fenugreek components as potential therapeutics for
metabolic syndrome (Table 2).
Considering that the pathophysiology of type 2 diabetes
typically progresses from insulin resistance to a failure of
pancreatic b-cells to secrete sufficient insulin to control gly-
cemia (61), the demonstrated insulinotropic properties of
4-OH-Ile suggest that it has potential as an antidiabetic
pharmacologic compound. A particularly attractive feature
of 4-OH-Ile is that it exhibits its secretory effect on insulin
only in the presence of elevated glucose ($8.3 mmol/l) con-
centrations (57). This could potentially overcome a common
drawback of sulfonylureas, which carry the risk of inducing






/advances/article/6/2/189/4558039 by Louisiana State U
niversity user on 24 Septem
ber 2021
hypoglycemia (69). Although several studies have demon-
strated that 4-OH-Ile stimulates insulin secretion by direct
action on pancreatic islets, there is also recent evidence that
4-OH-Ile can restore insulin sensitivity in skeletal muscle
with insulin resistance induced by treatment with FAs (66,
67). One recent study has produced similar findings in 3T3-L1
adipocytes, where 4-OH-Ile restored insulin sensitivity and
attenuated TNF-a expression in response to palmitate-induced
insulin resistance (68). The effect of 4-OH-Ile in potentiating
glucose-dependent insulin secretion and its insulin-sensitizing
properties, combined with its absence of acute toxicity, indicate
that this novel amino acid found in fenugreek could play a part
in strategies using natural products to combat metabolic
syndrome.
Soluble Fiber
Dietary fiber is widely accepted as a critical component of
sound nutrition and there is substantial evidence for the
role of fiber in health maintenance (70, 71). Fenugreek is
rich in dietary fiber, which comprises between 45% and
50% of the seeds of the plant that are commonly used in
cooking (72, 73). The fiber component of fenugreek (32%
insoluble and 13% soluble) (72) seeds is largely made up
of galactomannans, which are polysaccharides consisting
of a mannose backbone linked to galactose side groups
(74). The dietary fiber fraction of fenugreek has been stud-
ied for its biologic effect, particularly in a diabetic context,
and has been found to enhance glycemic control. This effect
of the fiber content of fenugreek has been attributed to its abil-
ity to inhibit lipid and carbohydrate-hydrolyzing enzymes in
the digestive system (75–78), which is a well-established
mechanism by which fiber has been shown to inhibit lipid
and glucose absorption (79) and thereby decrease postprandial
hyperglycemia and hyperlipidemia (80, 81). Although syn-
thetic disaccharidase and lipase inhibitors are effective in re-
ducing glucose and lipid concentrations, their use often has
undesirable side effects, including diarrhea and abdominal
pain (82). Lipase and glucosidase inhibitors derived from bo-
tanical sources in the diet could be useful in this regard be-
cause they tend to be well tolerated and have relatively
benign side effect profiles compared with many synthetics.
Data from animal studies have provided evidence that fi-
ber isolated from fenugreek has beneficial effects on several
markers pertaining to metabolic disease. The soluble dietary
fiber fraction isolated from fenugreek suppressed postpran-
dial hyperglycemia and lowered serum lipids in diabetic rats
(75, 83). These effects were attributed to delayed gastric
emptying of carbohydrate, inhibition of intestinal lipase
and sucrase activity, and increased gut motility. Interestingly,
these authors also found that the fiber fraction increased
both insulin-stimulated and basal glucose uptake in 3T3-
L1 adipocytes and augmented liver glycogen content (75).
These data argue in favor of increased insulin action in pe-
ripheral tissues induced by fiber isolated from fenugreek.
Similar findings have been reported in rats in which a compar-
ison study of different types of fiber resulted in decreased lip-
idemia because of reduced hepatic production of VLDL (84).
Fiber from fenugreek has also been demonstrated to atten-
uate the damaging effects of an atherogenic diet in rats in
which decreases in serum LDL oxidation and homocysteine
TABLE 2 Effects of 4-OH-Ile and isolated soluble fiber from fenugreek on metabolic syndrome1
Fenugreek derivative Model Experimental outcome Reference
4-OH-Ile Isolated human and rat pancreas [GSIS Sauvaire et al. (57)
4-OH-Ile Normal and type 2 diabetic
rats, isolated rat islets
[Oral glucose tolerance, [GSIS Broca et al. (59)
4-OH-Ile Isolated rat islets [GSIS Broca et al. (60)
4-OH-Ile Zucker fa/fa rats, high fat
+ sucrose-fed rats
[Oral glucose tolerance, [IS, YHGP, [PI3K, YFI Broca et al. (61)
4-OH-Ile Hamsters YSerum TG, YTC, YFFA, [HDL:TC Narender et al. (62)
4-OH-Ile Type 2 diabetic rats YBG, [ serum HDL, YALT, YAST Haeri et al. (63)
4-OH-Ile C57BL/db/db mice YBG, YFI, Yserum TG, Yserum TC, Yserum LDL,
[serum HDL
Singh et al. (64)
4-OH-Ile Type 1 diabetic rats YBG, Yserum TC, Yserum LDL, Yserum TG, [serum HDL Haeri et al. (65)
4-OH-Ile Skeletal muscle (L6 myocytes) [Glucose uptake, [pAkt, [PI3K, [GLUT4 Jaiswal et al. (66)
4-OH-Ile Insulin-resistant skeletal
muscle (L6 myocytes)
[pIRS-1, [PI3K, [pAkt, YROS, YNF-kB, YJNK1/2,
Yp38 MAPK
Maurya et al. (67)
4-OH-Ile Insulin-resistant 3T3 L1 adipocytes YTNF-a, [glucose uptake Yu et al. (68)
Soluble fiber Type 1 and type 2 diabetic rats YPostprandial glucose, Ysucrase activity, YBG,
[liver glycogen, YROS
Hannan et al. (75)
Soluble fiber Lean and obese rats YIntestinal glucose uptake Srichamroen et al. (76)
Soluble fiber Diabetic rats YLipase activity, Ylipid absorption, YBG, YALT, YAST,
Yuric acid
Hamden et al. (77)
Soluble fiber Obese rats YBody weight, Yserum TG, Yserum TC, YHMG-CoA
reductase activity, [biliary cholesterol excretion
Ramulu et al. (78)
Soluble fiber Obese rats YBody weight, Yfat pad weight, YBG, YFI, YALT, YAST,
YLDH, YTBARS, Yserum TC, [GSH, [SOD, [catalase
Kumar et al. (73)
1 ALT, alanine aminotransferase; AST, aspartate aminotransferase; BG, blood glucose; FI, fasting insulin; GLUT4, glucose transporter 4; GSH, reduced glutathione; GSIS, glucose-
stimulated insulin secretion; HGP, hepatic glucose production; HMG-CoA, b-hydroxy-b-methylglutaryl CoA; IS, insulin sensitivity; JNK, c-Jun N-terminal kinase; LDH, lactate
dehydrogenase; pAkt, Akt phosphorylated on Ser473; PI3K, phosphatidylinositide 3-kinase; pIRS-1, insulin receptor substrate 1 tyrosine phosphorylation; ROS, reactive oxygen
species; SOD, superoxide dismutase; TC, serum total cholesterol; 4-OH-Ile, 4-hydroxyisoleucine; [, increase in amount of incidence; Y, decrease in amount or incidence.
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were observed with concurrent increases in glutathione and
a-tocopherol (85). Improvements in glucose tolerance, di-
minished plasma TGs, and reduced visceral fat accumulation
have also been reported in rats fed a high-sucrose diet (86).
Galactomannan’s inhibition of intestinal glucose uptake and
antihyperlipidemic effect has been confirmed (76, 78). In ad-
dition to these effects, fenugreek galactomannan has also dis-
played protective effects on hepatic and renal function in a
diabetic context (77). Treatment with galactomannan reduced
serum concentrations of aspartate aminotransferase, alanine
aminotransferase, lactate dehydrogenase, urea, and creatinine
in streptozotocin-induced diabetic rats (77).
The abundant dietary fiber component of fenugreek,
composed mainly of the indigestible polysaccharide galacto-
mannan, has been isolated and shown to exhibit antidiabetic
properties (75–78, 86). These properties appear to be medi-
ated by the ability of galactomannan to reduce absorption of
dietary carbohydrates and lipids by inhibition of intestinal
lipases and carbohydrate-hydrolyzing enzymes (75–77). Ad-
ditionally, galactomannan has demonstrated antiatherogenic
effects via decreased serum LDL oxidation and homocyste-
ine (85). Galactomannan can also exert protective effects
on the liver and kidney in a diabetic context (77). These
findings indicate that the beneficial effects of fenugreek
are, at least in part, mediated by its fiber content. Future
studies aimed at assessing the relative contribution of fiber
from fenugreek compared with its other bioactive constitu-
ents on metabolic health would be worthwhile. Also, re-
search that assesses the effect of fenugreek’s fiber content
on the gut microbiome could further clarify the mechanisms
by which fenugreek favorably affects metabolic health.
Conclusions and Future Directions
The preponderance of the evidence summarized in the pre-
sent review indicates that fenugreek has bioactive chemical
components potentially useful as a part of new strategies
to treat metabolic disease. Nonetheless, questions remain
and more experiments will be required. This is particularly
true when considering the available evidence from human
studies. Data from clinical trials evaluating the effect of fen-
ugreek on glycemia in people with diabetes indicate that
fenugreek intake could reduce fasting BG and glycated
hemoglobin (87). However, the results of these studies
have been inconsistent and methodologic concerns exist.
For example, participants have varied in terms of their dia-
betes status, fenugreek dosages have ranged widely from as
low as <2 g/d to as much as 25 g/d, the durations of the stud-
ies vary considerably, the fenugreek preparations used in
these studies have not been standardized or consistently
tested for chemical composition, and the randomization
methods, blinding protocols, and allocation concealment
methods have not been consistently reported (87). Until re-
sults from clinical trials that overcome these methodologic
issues become available, there remains insufficient evidence
to support recommending the use of fenugreek as a therapeu-
tic agent against diabetes. In addition to these concerns regard-
ing human clinical trials, well-controlled studies designed to
determine the relative mechanistic contributions to enhanced
insulin sensitivity, reduced lipidemia, and improved liver and
cardiovascular status conferred by whole extracts of fenugreek
vs. individual bioactive components are necessary to better de-
fine how effects of this botanical are mediated.
The beneficial effects of fenugreek on metabolic status are
better characterized in some tissues than in others. Adipose
tissue in particular remains to be explored in greater detail.
Healthy fat cells are indispensable to robust metabolic health
by virtue of their endocrine function and capacity to safely
store lipids. The effect of fenugreek on adipocyte function
has only begun to be studied. Although there is some evi-
dence to suggest that fenugreek could positively affect fat
cell development and function (14, 23), these results await
independent confirmation and more detailed characteriza-
tion of the effect of fenugreek on both the fat cell directly
and its interaction with other insulin-sensitive tissues via
adipokine secretion. The possibility exists that fenugreek
could exert global effects on metabolism that might promote
overall health by enhancing adipocyte function.
The gut microbiome is a burgeoning area of research in-
terest because of the complex role played by intestinal mi-
crobes in health and disease (88–90). In mice, evidence
has demonstrated that changing the gut microbiome by fecal
transplantation induces changes in metabolic phenotype
and that several health conditions can be triggered by dis-
ruption of the intestinal microflora (91, 92). Furthermore,
it has been shown that diet can adversely or beneficially
modulate the gut microbiome and thus can have a potentially
dramatic influence on health and disease (93). The soluble fi-
ber content of fenugreek modulates gastrointestinal motility,
gastric emptying, and digestive enzymes and thus presents a
plausible general mechanism by which fenugreek could alter
the gut microbiome. Future research directed at exploring
whether and how fenugreek might favorably affect the intes-
tinal microbial environment has the potential to reveal new
insights into how natural products such as fenugreek could
serve to ameliorate the burden of metabolic disease.
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